Reviewing Innoviva Inc. (INVA)’s and Veracyte Inc. (NASDAQ:VCYT)’s results

As Biotechnology businesses, Innoviva Inc. (NASDAQ:INVA) and Veracyte Inc. (NASDAQ:VCYT), are affected by contrast. This especially applies to their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innoviva Inc. 261.00M 5.56 395.06M 1.65 10.69
Veracyte Inc. 85.85M 8.63 28.33M -0.81 0.00

In table 1 we can see Innoviva Inc. and Veracyte Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Innoviva Inc. and Veracyte Inc.

Net Margins Return on Equity Return on Assets
Innoviva Inc. 151.36% -104.6% 60.2%
Veracyte Inc. -33.00% -65.7% -33.9%

Volatility and Risk

Innoviva Inc. has a 2.22 beta, while its volatility is 122.00% which is more volatile than S&P 500. Veracyte Inc. on the other hand, has 0.67 beta which makes it 33.00% less volatile compared to S&P 500.

Liquidity

Innoviva Inc.’s Current Ratio and Quick Ratio are 28.2 and 28.2 respectively. The Current Ratio and Quick Ratio of its competitor Veracyte Inc. are 9.1 and 8.8 respectively. Innoviva Inc. therefore has a better chance of paying off short and long-term obligations compared to Veracyte Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Innoviva Inc. and Veracyte Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Innoviva Inc. 0 0 0 0.00
Veracyte Inc. 0 1 0 2.00

Insider & Institutional Ownership

Innoviva Inc. and Veracyte Inc. has shares owned by institutional investors as follows: 75.4% and 94.3%. Insiders owned 0.6% of Innoviva Inc. shares. Insiders Competitively, owned 0.2% of Veracyte Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Innoviva Inc. -3.5% 10.33% 21.27% 21.1% 36.8% 24.17%
Veracyte Inc. 2.04% -10.85% 11.02% 58.3% 94.85% 91.27%

For the past year Innoviva Inc. has weaker performance than Veracyte Inc.

Summary

On 8 of the 12 factors Innoviva Inc. beats Veracyte Inc.

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.

Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The companyÂ’s products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.